Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR
Biotech
Patient dies after receiving Intellia's CRISPR therapy
Both phase 3 studies remain on hold as the biotech works to understand liver-related events seen in the trials and to develop a risk-mitigation plan.
Nick Paul Taylor
Nov 7, 2025 5:25am
FDA puts Intellia CRISPR trials on hold over raised liver enzyme
Oct 30, 2025 6:37am
Intellia pauses phase 3 CRISPR trials after patient hospitalized
Oct 27, 2025 9:45am
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal
Oct 6, 2025 7:00am
ARPA-H unveils programs to develop custom gene editing therapies
Sep 26, 2025 10:41am
